Cargando…

Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds

OBJECTIVE: Depression represents one of the most severe psychiatric disorders, characterized by low mood episodes, as well as loss of interest. Major Depressive Episodes (MDE) treatment relies primarily on monoaminergic prescriptions. However, although the presence of many antidepressant medications...

Descripción completa

Detalles Bibliográficos
Autores principales: Girone, Nicolaja, Benatti, Beatrice, Molteni, Laura, Cassina, Niccolò, Giacovelli, Luca, Arici, Chiara, Dell’Osso, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Giovanni Fioriti Editore srl 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375276/
https://www.ncbi.nlm.nih.gov/pubmed/37522109
http://dx.doi.org/10.36131/cnfioritieditore20230303
_version_ 1785079000918392832
author Girone, Nicolaja
Benatti, Beatrice
Molteni, Laura
Cassina, Niccolò
Giacovelli, Luca
Arici, Chiara
Dell’Osso, Bernardo
author_facet Girone, Nicolaja
Benatti, Beatrice
Molteni, Laura
Cassina, Niccolò
Giacovelli, Luca
Arici, Chiara
Dell’Osso, Bernardo
author_sort Girone, Nicolaja
collection PubMed
description OBJECTIVE: Depression represents one of the most severe psychiatric disorders, characterized by low mood episodes, as well as loss of interest. Major Depressive Episodes (MDE) treatment relies primarily on monoaminergic prescriptions. However, although the presence of many antidepressant medications, their efficacy is still partial. A promising intervention to improve antidepressant treatment may be the use of adjunctive nutraceuticals. Aim of the present study was to assess the efficacy of a N-Acetyl-cysteine, S-Adenosyl-L-Methionine and Folic acid’s combination for the treatment of depressive symptoms in a sample of MDE patients. METHOD: Fifty outpatients with a MDE diagnosis in the context of different psychiatric disorders such as Major Depression, Bipolar Disorder, Anxiety disorders, and Personality disorders were recruited. The sample was divided into different groups based on the nutraceutical administration: a) concurrently with an AD (starter group); b) add-on to an already prescribed treatment; c) single treatment. RESULTS: A significant reduction of CGI-Severity and Improvement scores from baseline to the end of treatment was found. Moreover, the starter group showed a significantly greater CGI-Improvement score compared to the other groups. Ninety-four percent of patients did not show any side effects. CONCLUSIONS: The present study showed promising results for the use of nutraceuticals in the add-on treatment of MDE. Those compounds may be considered a versatile, tolerable, and effective add-on treatment for the reduction of depressive symptoms impact and for improving the functioning of patients affected by MDE.
format Online
Article
Text
id pubmed-10375276
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Giovanni Fioriti Editore srl
record_format MEDLINE/PubMed
spelling pubmed-103752762023-07-29 Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds Girone, Nicolaja Benatti, Beatrice Molteni, Laura Cassina, Niccolò Giacovelli, Luca Arici, Chiara Dell’Osso, Bernardo Clin Neuropsychiatry Research Paper OBJECTIVE: Depression represents one of the most severe psychiatric disorders, characterized by low mood episodes, as well as loss of interest. Major Depressive Episodes (MDE) treatment relies primarily on monoaminergic prescriptions. However, although the presence of many antidepressant medications, their efficacy is still partial. A promising intervention to improve antidepressant treatment may be the use of adjunctive nutraceuticals. Aim of the present study was to assess the efficacy of a N-Acetyl-cysteine, S-Adenosyl-L-Methionine and Folic acid’s combination for the treatment of depressive symptoms in a sample of MDE patients. METHOD: Fifty outpatients with a MDE diagnosis in the context of different psychiatric disorders such as Major Depression, Bipolar Disorder, Anxiety disorders, and Personality disorders were recruited. The sample was divided into different groups based on the nutraceutical administration: a) concurrently with an AD (starter group); b) add-on to an already prescribed treatment; c) single treatment. RESULTS: A significant reduction of CGI-Severity and Improvement scores from baseline to the end of treatment was found. Moreover, the starter group showed a significantly greater CGI-Improvement score compared to the other groups. Ninety-four percent of patients did not show any side effects. CONCLUSIONS: The present study showed promising results for the use of nutraceuticals in the add-on treatment of MDE. Those compounds may be considered a versatile, tolerable, and effective add-on treatment for the reduction of depressive symptoms impact and for improving the functioning of patients affected by MDE. Giovanni Fioriti Editore srl 2023-06 /pmc/articles/PMC10375276/ /pubmed/37522109 http://dx.doi.org/10.36131/cnfioritieditore20230303 Text en © 2023 Giovanni Fioriti Editore s.r.l. This is an open access article. Distribution and reproduction are permitted in any medium, provided the original author(s) and source are credited.
spellingShingle Research Paper
Girone, Nicolaja
Benatti, Beatrice
Molteni, Laura
Cassina, Niccolò
Giacovelli, Luca
Arici, Chiara
Dell’Osso, Bernardo
Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title_full Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title_fullStr Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title_full_unstemmed Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title_short Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds
title_sort partial response to antidepressant treatment: the role of nutraceutical compounds
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375276/
https://www.ncbi.nlm.nih.gov/pubmed/37522109
http://dx.doi.org/10.36131/cnfioritieditore20230303
work_keys_str_mv AT gironenicolaja partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT benattibeatrice partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT moltenilaura partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT cassinaniccolo partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT giacovelliluca partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT aricichiara partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds
AT dellossobernardo partialresponsetoantidepressanttreatmenttheroleofnutraceuticalcompounds